and tricyclic antidepressants by Hotopf et al (1997) . Although the result of the compar ison of newer tricyclic agents and SSRIs is not surprising, we were unclear about some methodological points relevant to the conclusions.
In the treatment studies of newer TCAS and SSRIs, patients discontinue treatment for various reasons such as lack of efficacy, adverse events or early treatment response. Also, there may be wider variations in the dosage ranges for some newer tricyclics and SSRIs compared with others, and in the rate of dosage escalation to achieve the BNF dosages. We were not clear whether these sources of heterogeneity had been ad dressed, or if not, whether these would have affected the conclusions reached.
A more serious problem is the method used in the trials to establish lack of efficacy and what constitutes an adverse event. Some studies use different outcome measures and different response criteria on the basis of change in score of these measures. Some studies use different methods to enquire about possible adverse events or adjust for the effects of preceding somatic and cogni tive complaints at study entry. These factors may affect the comparability of such studies. Also, we would be interested to know whether there were differences in the time onset of discontinuation (i.e. â€˜¿ early' or â€˜¿ late') in these studies.
Another important point is the likely rate of discontinuation of antidepressants after response in the acute phase of illness, that is in the maintenance phase; as the studies referenced mostly appear to have been of short duration. If such information was available this would be of great interest, as some clinicians argue that SSRIs might be more acceptable in maintenance treatment than tricyclics, yet we are not aware of any good evidence that this holds for newer classes of tricyclic antidepressants such as lofepramine.
Hotopf; H. Hardy, R. a Lewis. G. (I@7) Discontinuation ratesof SSRIs and tricyclic antidepressants: a meta-analysis and investigationof heterogeneity. BritishJournal of Psychiatry. 170.120â€" 127.
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Authors' reply: We thank the correspon dents for their comments on our paper. Throughout the paper we emphasised that SSRIs. This is not to deny that there may be a difference, but it is not shown by these results and is likely to be extremely small. Third, the authors investigate sources of heterogeneity as a possible indicator of differences between groups of drugs. The overall result does demonstrate statistical heterogeneity. If this is due to differences between the antidepressant groups, then exclusion of these groups should reduce the heterogeneity. In fact the heterogeneity is slightly increased by excluding newer TCAs and heterocyclics, indicating that there must be some other explanation. While some sources of heterogeneity are examined others are not, for example dose of TCA used in the study or the study quality/size.
Therefore Hotopf et al's conclusion that the difference in drop-outs between tricyc lics and SSRIs may be explained by the â€˜¿ old versus newer' TCA distinction is not war ranted on the evidence produced. Systematic reviews and meta-analyses are helpful in clarifying the limits of our knowledge but we mustbe verycarefulnot to go beyond the evidence; otherwise we play into the hands of critics of evidence-based medicine and bring the process into disrepute. 1995) . They go on to suggest that the poorer tolerability may be accounted for by studies using old TCAs (amitriptylme and imipra mine), whereas newer tricyclics have equal tolerability to SSRIs. However, this distinc tion, and the interpretation of their results, is fraught with difficulties. First, there is no pharmacological justi fication for the separation into â€˜¿ old' and â€˜¿ newer' TCAs. Examination of receptor binding affinity for individual drugs (pre sumed to relate to propensity to cause side effects) shows no good reason to divide them in the way Hotopf et a! have done (Richelson, 1996) ; the division may have been â€˜¿ proposed in advance' but is no less arbitrary for that. Second, in interpreting the results the authors make the fundamental mistake of equating â€˜¿ no evidence of differ ence' with â€˜¿ evidence of no difference' (Ox man, 1994). The results for old TCAs compared with SSRIs do reach statistical significance but those for newer TCAs, with a smaller number of studies and wider confidence intervals, do not. This does not mean that old TCAs are different to SSRIs whereas newer TCAs are not. The odds and risk ratios for old and newer TCA groups differ very little and are certainly not significantly different from each other. It is likely that dividing the TCAs in any way would result in statistical significance for the larger group but not for the smaller group. Therefore, it is statistical sophistry or naÃ¯vetyto claim that old and newer TCAs differ in their tolerability compared with crude drop-out rates from randomised con trolled trials (RCTs) have their limitations as outcome measures.
We have stated elsewhere (Hotopf et al, 1996a,b) that the important question of comparable tolerabil ity and cost-effectiveness of SSRIsand tricyclics will not be resolved without a large primary-care-based RCT.
We deliberately did not subdivide reason for drop-out according to lack of efficacy or side-effects. This was because we believe drop-out from RCTs depends upon multiple factors and that the usual simple classifica tion between side-effects and lack of efficacy is an over-simplification which may be especially subject to observer bias (Hotopf eta!, 1996a) .
We have addressed some of Lynch & Curran's points in another paper (Hotopf et a!, 1997, in press), in which we assessed methodology of the RCTs. Dosages of tricyclics are often inadequately reported in trials: while some studies allow as wide a range of dosages of tricyclics as 75â€"300mg in their protocols, approximately one-quar ter did not report a mean or median dose attained. Similarly, while the point at which drop-out takes place is important, it is also frequently not reported. Lynch & Curran also mention the duration of studies as another source of heterogeneity. We believe this is less important since two-thirds of studies were of six weeks' duration.
Anderson & Mortimore flatter us by suggesting our paper may be sufficiently widely read to bring evidence-based mcd icine into disrepute.
Their comments mainly concern our decision to classify RD's according to the â€˜¿ generation' of tricyclic used. Evidence-based medicine aims to apply research findings to practical clinical problems. The tendency of most trials to use the oldest TCAs is of limited clinical relevance (at least in primary care) as these are not very widely used. It is more relevant to compare current com monly prescribed alternatives, and this was our rationale for the subdivision. Before new (and relatively expensive) drugs such as the SSRIsare widely prescribed,a clear advantage must be demonstrated over the older medications. The absence of any evidence that the newer TCAs have lower drop-out rates than SSRIs is, therefore, important.
It is possible, perhaps even likely, that the newer TCAs do have higher drop-out rates. We mentioned the lack of power and gave confidence intervals so readers could make up their own minds, so Anderson & Mortimore's comments regarding â€oe¿ statistical sophistry or naÃ¯vetyâ€• are unfounded.
Anderson & Mortimore's third com ment appears to contradict their other points. The analysis according to type of antidepressant shows that significant hetero geneity remained for the old tricyclics, but not for the other two groups, suggesting that while other sources of heterogeneity exist in the older tricyclics, they do not for the other drugs. This seems to support our classifica tion rather than to refute it. There will always be uncertainty regarding the investi gation of heterogeneity (Thompson, 1994) and there may be more than one feasible explanation for any given meta-analysis. (1996) , included the costs associated with antidepressant overdose in their compari sons. We believe that while some attention has been paid to the mortality associated with TCA overdose there has been little consideration of its morbidity and the consequent costs.
In an audit of 404 cases of deliberate self-harm presenting to the accident and emergency department at Addenbrooke's Hospital, Cambridge, in the six-month period between 1 January and 30 June 1996 there were 75 cases of deliberate self poisoning with antidepressants. There were 35 cases of deliberate self-poisoning with TCAs and 40 cases of SSRI overdose. In one case the antidepressant was not identified, one case was of deliberate self-poisoning with trazodone and in two cases an SSRI was taken with a TCA. Thirty of the 35 cases of TCA overdose were admitted to Addenbrooke's Hospital, including six who were admitted to the intensivetherapy unit (ITU) and three admitted to the cardiac monitoring unit (CMU). One of these patients died in liii. Of the subgroup of 16 cases involving newer TCAs (lofepramine and dothiepin), 13 were admitted to Adden brooke's including two admitted to flU and one admitted to CMU. Twenty-five of the 40 cases of SSRI overdose were admitted to Addenbrooke's and none of these was admitted to flU or CMU.
The Addenbrooke's Hospital NHS Trust has recently costed a bed in flU for one day at Â£1530and a bed in CMU at Â£340.These figures represent costs approximately 15 times and three times, respectively, those of a bed on a general ward. This audit indicates that the cost of treating antidepressant overdoses is considerably greater for TCAS than for SSRIs. , 1975) . Based on these find ings, Jabourian et a! argued that cognitive impairments are a major risk factor for falls. It is questionable whether all patients with
